Intellia Flags In Vivo CRISPR Knockout Platform As Key Priority For 2023
After ending 2022 with more than $1bn in cash, the US firm is keen to validate its in vivo approach to gene therapy with investigational new drug applications and pivotal trials lined up for two core rare disease programs.
You may also be interested in...
Intellia continues to expand across immuno-oncology, adding the promise of natural killer cells to its pipeline.
Real-world cases of retinal vasculitis linked with Syfovre for geographic atrophy in age-related macular degeneration may have resulted from a material used in a specific filter needle, the US firm revealed, as analysts remained optimistic on the product.